Plus Therapeutics appoints Norman LaFrance as CMO, effective Dec 8, 2021

PLUS THERAPEUTICS, INC.

Dr. LaFrance will receive $440K base salary, 35% target bonus, and options for 120K shares vesting over 4 years.
He brings 40 years in nuclear medicine and pharma, previously CMO at Jubilant Pharma Ltd.
Appointment effective Dec 8, 2021; LaFrance will lead clinical development, regulatory, and medical affairs.
Severance package includes 12 months salary + target bonus + COBRA premium if terminated without cause.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Norman LaFrance

Chief Medical Officer

PSTV · PLUS THERAPEUTICS, INC.

Effective: 2021-12-08
Filed: September 13, 2021, 7:59 PM ET

On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Norman LaFrance was appointed as Chief Medical Officer at PLUS THERAPEUTICS, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.

View on SEC.gov

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-270847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.